GLP-1 Multi-Agonist & Combination Therapies Market
完整報告名稱與涵蓋範圍
GLP-1 Multi-Agonist & Combination Therapies Market Size, Share & Trends Analysis Report, By Mechanism (GIP/GLP-1 Dual Agonists, GLP-1/Glucagon Dual Agonists, Triple Agonists (GIP/GLP-1/Glucagon), GLP-1 Combinations with Amylin and Other Agents), By Indication (Obesity and Weight Management, Type 2 Diabetes, Cardiovascular and Renal Risk Reduction, MASH and Other Metabolic Diseases), By Route of Administration (Subcutaneous Injection, Oral), By Distribution Channel, By Region, and Segment Forecasts, 2026-2035
報告摘要
The GLP-1 multi-agonist and combination therapies market comprises incretin-based medicines that act on GLP-1 together with GIP, glucagon or amylin receptors, whether as single unimolecular agonists or fixed-dose combinations, for obesity, type 2 diabetes, cardiovascular and renal risk reduction and metabolic liver disease. Single-target GLP-1 agonists are excluded except where used as a component of a combination product.
The category is expanding on the back of the commercial success of the first GIP/GLP-1 dual agonist and a deep late-stage pipeline of triple agonists, glucagon-containing dual agonists and amylin combinations that promise greater weight loss, better tolerability or muscle-sparing profiles. Sponsors are also pursuing oral small-molecule and peptide formulations, monthly dosing and maintenance regimens to broaden access and improve persistence. Manufacturing scale-up of peptides and devices, outcomes trial readouts in heart failure, sleep apnea and MASH, and payer negotiations over coverage for obesity remain decisive commercial variables.
North America and Europe will remain the largest markets by value, while China is emerging as both a major demand pool and a source of innovator pipelines through domestic biotechnology companies. Competition pits the two incretin incumbents against large pharmaceutical entrants and well-funded biotechnology companies, with licensing deals for Chinese-origin assets reshaping the landscape.
The InsightAce study provides US$ revenue forecasts for every mechanism, indication, route of administration and distribution channel and regional segment over 2026-2035, plus segment trend analysis, competitive landscape mapping and profiles of leading participants.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global GLP-1 Multi-Agonist & Combination Therapies Market Snapshot
Chapter 4. Global GLP-1 Multi-Agonist & Combination Therapies Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Mechanism Estimates & Trend Analysis
5.1. Mechanism & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Mechanism:
5.2.1. GIP/GLP-1 Dual Agonists
5.2.2. GLP-1/Glucagon Dual Agonists
5.2.3. Triple Agonists (GIP/GLP-1/Glucagon)
5.2.4. GLP-1 Combinations with Amylin and Other Agents
Chapter 6. Market Segmentation 2: By Indication Estimates & Trend Analysis
6.1. Indication & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Indication:
6.2.1. Obesity and Weight Management
6.2.2. Type 2 Diabetes
6.2.3. Cardiovascular and Renal Risk Reduction
6.2.4. MASH and Other Metabolic Diseases
Chapter 7. Market Segmentation 3: By Route of Administration Estimates & Trend Analysis
7.1. Route of Administration & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Route of Administration:
7.2.1. Subcutaneous Injection
7.2.2. Oral
Chapter 8. Market Segmentation 4: By Distribution Channel Estimates & Trend Analysis
8.1. Distribution Channel & Market Share, 2026 & 2035
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Distribution Channel:
8.2.1. Hospital Pharmacies
8.2.2. Retail Pharmacies
8.2.3. Online and Telehealth Pharmacies
Chapter 9. GLP-1 Multi-Agonist & Combination Therapies Market: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. United States
9.1.2. Canada
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. South Korea
9.3.5. Australia
9.3.6. Southeast Asia
9.3.7. Rest of Asia Pacific
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Middle East & Africa
9.5.1. GCC Countries
9.5.2. South Africa
9.5.3. Rest of Middle East & Africa
Chapter 10. Competitive Landscape
10.1. Company Market Positioning Analysis
10.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 11. Company Profiles
11.1. Eli Lilly and Company
11.2. Novo Nordisk A/S
11.3. Amgen Inc.
11.4. Boehringer Ingelheim International GmbH
11.5. Zealand Pharma A/S
11.6. Roche Holding AG
11.7. AstraZeneca plc
11.8. Pfizer Inc.
11.9. Viking Therapeutics, Inc.
11.10. Structure Therapeutics Inc.
11.11. Innovent Biologics, Inc.
11.12. Hengrui Pharmaceuticals Co., Ltd.
11.13. Sciwind Biosciences
11.14. Metsera, Inc.
11.15. Kailera Therapeutics, Inc.
圖表清單 List of Tables & Figures
Table 1. Global GLP-1 Multi-Agonist & Combination Therapies Revenue Forecast by Mechanism, 2026-2035 (US$ Mn)
Figure 1. Global GLP-1 Multi-Agonist & Combination Therapies Market Snapshot, 2026 & 2035
Table 2. Global GLP-1 Multi-Agonist & Combination Therapies Revenue Forecast by Indication, 2026-2035 (US$ Mn)
Figure 2. Global GLP-1 Multi-Agonist & Combination Therapies Market Share by Indication, 2026 & 2035
Table 3. Global GLP-1 Multi-Agonist & Combination Therapies Revenue Forecast by Route of Administration, 2026-2035 (US$ Mn)
Figure 3. Multi-Agonist Pipeline by Mechanism, Phase and Expected Launch Window, 2026-2032
Table 4. Global GLP-1 Multi-Agonist & Combination Therapies Revenue Forecast by Distribution Channel, 2026-2035 (US$ Mn)
Figure 4. Weight-Loss Efficacy and Tolerability Benchmarking Across Incretin Mechanisms
Table 5. North America GLP-1 Multi-Agonist & Combination Therapies Revenue by Country, 2026-2035 (US$ Mn)
Figure 5. Asia Pacific GLP-1 Multi-Agonist & Combination Therapies Growth Opportunity Analysis
Table 6. Europe GLP-1 Multi-Agonist & Combination Therapies Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Peptide Manufacturing and Device Capacity Constraints Affecting Launch Volumes
Table 7. Asia Pacific GLP-1 Multi-Agonist & Combination Therapies Revenue by Country, 2026-2035 (US$ Mn)
Figure 7. Competitive Positioning of Key GLP-1 Multi-Agonist & Combination Therapies Market Participants
Table 8. Latin America and Middle East & Africa GLP-1 Multi-Agonist & Combination Therapies Revenue Forecast, 2026-2035 (US$ Mn)
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們